open access

Vol 13, No 6 (2018)
Original Papers
Published online: 2019-02-13
Get Citation

Effect of sex on anticoagulant use for stroke prevention in atrial fibrillation: registry with 4,099 patients from a tertiary cardiology centre

Anna Szpotowicz, Iwona Gorczyca, Małgorzata Krzciuk, Beata Wożakowska-Kapłon
DOI: 10.5603/FC.2018.0122
·
Folia Cardiologica 2018;13(6):510-516.

open access

Vol 13, No 6 (2018)
Original Papers
Published online: 2019-02-13

Abstract

Atrial fibrillation (AF) is the most common supraventricular arrhythmia. AF is characterised by disorganised atrial activation which leads to an impairment of atrial haemodynamic function and, in turn, to serious clinical consequences such as increased risks of heart failure, thromboembolism, and death. AF prevalence increases with age; in people aged < 50 years, the prevalence is 0.1%, whereas in those aged > 85 years it is 17.8%. Although men have a higher risk of AF compared to women, in women, AF more often is symptomatic and associated with more serious complications. Because female sex is a risk factor for thromboembolism, in 2012 the European Society of Cardiology recommended the use of the CHA2DS2-VASc score, which scores 1 point for being female, in assessing the thromboembolic risk in patients with AF. Among hospitalised patients with AF (men and women), this study assessed the thromboembolic risk and evaluated anticoagulant use for stroke prevention.

Abstract

Atrial fibrillation (AF) is the most common supraventricular arrhythmia. AF is characterised by disorganised atrial activation which leads to an impairment of atrial haemodynamic function and, in turn, to serious clinical consequences such as increased risks of heart failure, thromboembolism, and death. AF prevalence increases with age; in people aged < 50 years, the prevalence is 0.1%, whereas in those aged > 85 years it is 17.8%. Although men have a higher risk of AF compared to women, in women, AF more often is symptomatic and associated with more serious complications. Because female sex is a risk factor for thromboembolism, in 2012 the European Society of Cardiology recommended the use of the CHA2DS2-VASc score, which scores 1 point for being female, in assessing the thromboembolic risk in patients with AF. Among hospitalised patients with AF (men and women), this study assessed the thromboembolic risk and evaluated anticoagulant use for stroke prevention.
Get Citation

Keywords

stroke, atrial fibrillation, sex

About this article
Title

Effect of sex on anticoagulant use for stroke prevention in atrial fibrillation: registry with 4,099 patients from a tertiary cardiology centre

Journal

Folia Cardiologica

Issue

Vol 13, No 6 (2018)

Pages

510-516

Published online

2019-02-13

DOI

10.5603/FC.2018.0122

Bibliographic record

Folia Cardiologica 2018;13(6):510-516.

Keywords

stroke
atrial fibrillation
sex

Authors

Anna Szpotowicz
Iwona Gorczyca
Małgorzata Krzciuk
Beata Wożakowska-Kapłon

References (20)
  1. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995; 155(5): 469–473.
  2. Braunwald E. Shattuck lecture — cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997; 337(19): 1360–1369.
  3. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003; 290(8): 1049–1056.
  4. Heeringa J, Kuip Dv, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006; 27(8): 949–953.
  5. Camm AJ, Lip GYH, De Caterina R, et al. ESC Committee for Practice Guidelines-CPG, Document Reviewers, ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33(21): 2719–2747.
  6. Kirchhof P, Schmalowsky J, Pittrow D, et al. ATRIUM Study Group, ATRIUM investigators. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol. 2011; 100(10): 897–905.
  7. Nieuwlaat R, Capucci A, Camm AJ, et al. European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005; 26(22): 2422–2434.
  8. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009; 11(4): 423–434.
  9. Bednarski J, Cieszewska E, Strzelecki A, et al. Anticoagulant and antiplatelet therapy for stroke prevention in atrial fibrillation patients in the clinical practice of a single district hospital in Poland. Kardiol Pol. 2013; 71(12): 1260–1265.
  10. Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study. Turk Kardiyol Dern Ars . 2013; 41(2): 99–104.
  11. Doğan V, Başaran Ö, Beton O, et al. Gender-related differences in presentation and treatment of patients with non-valvular atrial fibrillation: results from RAMSES study. Turk Kardiyol Dern Ars. 2017; 45(1): 16–25.
  12. Lip GYH, Rushton-Smith SK, Goldhaber SZ, et al. GARFIELD-AF Investigators. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2015; 8(2 Suppl 1): S12–S20.
  13. Chan PS, Maddox TM, Tang F, et al. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol. 2011; 108(8): 1136–1140.
  14. Scowcroft ACE, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart. 2013; 99(2): 127–132.
  15. Łopatowska P, Tomaszuk-Kazberuk A, Młodawska E, et al. Management of patients with valvular and non-valvular atrial fibrillation in Poland: Results from Reference Cardiology University Center. Cardiol J. 2015; 22(3): 296–305.
  16. Shehab A, Zubaid M, Bhagavathula AS, et al. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) investigators. Sex differences in management and outcomes of patients with atrial fibrillation in the Middle East: Gulf survey of atrial fibrillation events (Gulf SAFE). PLoS One. 2017; 12(5): e0175405.
  17. Schnabel RB, Pecen L, Ojeda FM, et al. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart. 2017; 103(13): 1024–1030.
  18. Friberg L, Benson L, Rosenqvist M, et al. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ. 2012; 344: e3522.
  19. Avgil Tsadok M, Jackevicius CA, Rahme E, et al. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA. 2012; 307(18): 1952–1958.
  20. Loikas D, Forslund T, Wettermark B, et al. Sex and gender differences in thromboprophylactic treatment of patients with atrial fibrillation after the introduction of non-vitamin K oral anticoagulants. Am J Cardiol. 2017; 120(8): 1302–1308.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl